EP3536712

METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)

Filed

Sep 12, 2012

Technology

Chemistry · Biotechnology +1

UPC cases

EPO proceedings

Ownership history

As recorded at the EPO. Transfers made after the opposition period are recorded in national registers and may be missing here.

Regeneron Pharmaceuticals Inc.since Aug 9, 2019

Abstract

The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.

Litigation history

Date	Case	Division	Type	Outcome	Parties
Jul 14, 2025	UPC CoA 641/2025	Court of Appeal	Appeal	Locked	Sanofi Biotechnology SAS +1

Additional proceedings on this patent

Start 14-day free trialOutcomes, the additional proceedings and the register history.Already a user? Sign in